Transcription of The Stock Network Interview with Starpharma (ASX:SPL, US OTC:SPHRY:SPL), Chief Executive Officer, Cheryl Maley
Lel Smits: Starpharma is an innovative biotechnology company with two decades of experience in advancing dendrometh technology from the lab to the patient. The company’s mission is to help patients with significant illnesses such as cancer achieve improved health outcomes and quality of life through the application of its unique dendrometh platform technology. I’m joined today by Starpharma CEO Cheryl Maley to discuss more on the Stock Network.
Cheryl, welcome to the Stock Network.
Cheryl Maley: Thanks so much, Lel. Thanks for having me here today.
Lel Smits: Pleasure. Now, this quarter was a milestone period for Starpharma securing two major global partnerships with Genentech and Radiopharm Theragnostics demonstrating growing industry validation and commercial traction for Starharma’s DEP platform. How do these achievements position Starpharma for its next phase of growth?
Cheryl Maley: Yeah, I think it has been a fantastic quarter for Starpharma and we’re really excited about the opportunities that it presents as we go forward, not just relating to these partnerships, but for more partnerships and also for the work that we do with our technology.
So we have two clear priorities at Starpharma. The first is that we develop great assets using our technology and by great assets, I mean those that address significant unmet need, provide patient benefit and competitive advantage through our technology. And the second one is that we also provide that benefit and opportunity to strategic partners like the two that we just announced today.
So using our technology that they can provide more patient benefit and more competitive advantage as they go into commercialisation. So we’re super excited about the growth that can come from not just these partnerships, but more partnerships and our own asset development.
Lel Smits: Excellent and looking closer at those partnerships and commercial momentum with Genentech providing access to world-leading oncology expertise and Radiopharm expanding into radiopharmaceuticals, Starpharma’s DEP platform really now has gained very powerful industry endorsement. Can you outline a bit further how these collaborations highlight the commercial power of the DEP platform and also your plans to maintain this momentum?
Cheryl Maley: Yeah, well I think with both of those partnership announcements, they are on the back of both of those companies having some experience with the technology. And for us that has been super important because they get not only to experience the dendrite technology and the benefit that can bring, but they also get to experience the capability of the Starpharma team in using the technology and enabling them to use it in the future.
And so we’re, you know, as I said, we’re excited, but actually the opportunity that comes from that is their validation having had some experience with it in novel spaces and also our opportunity to continue different partnerships with other companies or broaden those within our existing partners. So there’s lots of commercial opportunities still to come.
Lel Smits: Wonderful and finally, Cheryl, looking ahead, what key milestones and development programs will drive Starpharma’s growth and also your value creation into FY26 and beyond?
Cheryl Maley: So we’re excited about this year and next year, particularly on the back of not just these announcements, but also where we’re at with our internal asset development. So the catalyst that investors should be looking out for would relate to our radio program. We have two radio assets that are being developed using our technology that will progress to clinic next year.
We also want to see the progression of our existing partnerships that they achieve the milestones that they are intending and also expanding partnerships. So more companies coming in to experiment and use and ultimately license our technology. And on the back of that, we have products that have the ability to be licensed and looking out for license announcements for those Starpharma assets.
Lel Smits: Certainly a lot of catalysts there, and I look forward to seeing the momentum continue. Cheryl, thank you for the update from Starpharma. Thanks so much, Lel.
Ends